Effects of Highly Active Antiretroviral Treatment on Liver and Kidney Functions

Main Article Content

Simon Bannison Bani
Christian Obirikorang
Kwabena O. Danquah
William K. B. A. Owiredu
Lawrence Quaye
Samuel A. Sakyi
Yussif Adams
Peter Paul M. Dapare
Moses Banyeh
Barnabas B. N. Gandau


Aim: This study assesses the effects of HAART on liver and renal functions in HIV infected individuals on HAART.

Study Design: Cross sectional study.

Place and Methods: This study was conducted in Tamale, Ghana from August, 2015 to November 2017.

Methodology: A total of 300 HIV infected participants with ages ranging from 19 to 79 years who have been administered with HAART for at least 6 months were recruited. Pre-HAART administration (baseline) demographic and clinical information, with initial liver and renal function test results were retrieved from the medical records of the participants present at the ART center. Post HAART administration blood sample (5 mLs) was taken from each participant into a gel separated vacutainer tube, allowed to clot and spun at 3000 rpm for 3 minutes to produce serum. The product (serum) was used for liver and renal function test analysis using a fully automated chemistry analyser (Vital Scientific Selectra Flexor XL).

Results: Of the study population, 72% were administered with AZT/3TC/EFV, 13% with AZT/3TC/NVP, 6.7% with TDF/3TC/LPV/r and TDF/3TC/NVP, 1% with AZT/3TC/EFV while 0.7% were administered with TDF/FTC/EFV. The following parameters were significantly increased post HAART administration; ALT (25.53 ± 16.90 to 30.87 ± 19.28 U/L), ALP (163.7 ± 141.0 to 215.2 ± 143.4 U/L), GGT (37.27 ± 25.21 to 53.19 ± 41.71 U/L), Total protein (73.97 ± 17.08 to 82.31 ± 11.62 g/L), Albumin (38.02 ± 9.331 to 41.01 ± 7.471 g/L), Globulin 38.02 ± 15.71 to 42.79 ± 25.20 (g/L). There were however significant reductions in Total bilirubin (12.13 ± 10.85 to 9.434 ± 4.560 µmol/L), Direct bilirubin (6.616 ± 5.770 to 4.184 ± 2.806 µmol/L), (Creatinine 73.19 ± 36.13 to 63.14 ± 27.14 µmol/L) and Urea (3.515 ± 2.552 to 3.011±1.274 mmol/L).

Conclusion: HAART improves renal function, induces elevation in liver enzymes, stimulates the production of plasma proteins and reduces serum bilirubin concentration.

Highly active antiretroviral therapy, HIV infection, LFT, RFT, HIVAN

Article Details

How to Cite
Bani, S. B., Obirikorang, C., Danquah, K. O., Owiredu, W. K. B. A., Quaye, L., Sakyi, S. A., Adams, Y., Dapare, P. P. M., Banyeh, M., & Gandau, B. B. N. (2020). Effects of Highly Active Antiretroviral Treatment on Liver and Kidney Functions. International STD Research & Reviews, 9(2), 8-16. https://doi.org/10.9734/ISRR/2020/v9i230109
Original Research Article


Onodugo OD, Chukwuka C, Onyedum C, Ejim E, Mbah A, Nkwo P, et al. Baseline renal function among antiretroviral therapy-naive, hiv-infected patients in Southeast Nigeria. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2014;13(5):476-80.

Ragwa FG, Waithaka SK, Ouma JH. Comparative renal function tests between HIV patients on and not on antiretrovirals and HIV negative individuals at Nyeri Provincial General Hospital, Nyeri County, Kenya. Int J Adv Multidiscip Res. 2017; 4(3):51-8.

Obirikorang C, Osakunor DNM, Ntaadu B, Adarkwa OK. Renal function in Ghanaian HIV-infected patients on highly active antiretroviral therapy: A case-control study. PloS one. 2014;9(6):e99469.

Franceschini N, Napravnik S, Eron Jr JJ, Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney international. 2005;67(4):1526-31.

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: Global dimension and perspectives. The Lancet. 2013;382(9888): 260-72.

Price JC, Thio CL. liver Disease in the Hiv–infected Individual. Clinical Gastroenterology and Hepatology. 2010; 8(12):1002-12.

Abraham AG, Althoff KN, Jing Y, Estrella MM, Kitahata MM, Wester CW, et al. End-stage renal disease among HIV-infected adults in North America. Clinical Infectious Diseases. 2014;60(6):941-9.

Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clinical Infectious Diseases. 2014;60(4): 627-38.

Zhang F, Dou Z, Yu L, Xu J, Jiao JH, Wang N, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clinical infectious diseases. 2008; 47(6):825-33.

Peters PJ, Moore DM, Mermin J, Brooks JT, Downing R, Were W, et al. Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney international. 2008;74(7):925-9.

Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides, Nucleotides and Nucleic Acids. 2001;20(4-7):641-8.

Reust CE. Common adverse effects of antiretroviral therapy for HIV disease. American Family Physician. 2011;83(12).

Reisler R, Liou S, Servoss J, Robbins G, Theodore D, Murphy R, et al, editors. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials. Program and abstracts of The 1st IAS Conference on HIV Pathogenesis and Treatment; 2001.

Reisler R, Liou S, Servoss J, Robbins G, Theodore D, Murphy R, et al, Editors. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials. Program and abstracts of The 1st IAS Conference on HIV Pathogenesis and Treatment; Buenos Aires, Argentina; 2001.

Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine. 1998; 338(13):853-60.

Becker S. Liver toxicity in epidemiological cohorts. Clinical Infectious Diseases. 2004; 38(2):S49-S55.

Bonacini M. Liver injury during highly active antiretroviral therapy: The effect of hepatitis C coinfection. Clinical Infectious Diseases. 2004;38(Supplement_2):S104-S8.

Shiferaw MB, Tulu KT, Zegeye AM, Wubante AA. Liver enzymes abnormalities among highly active antiretroviral therapy experienced and HAART naïve HIV-1 infected patients at Debre Tabor Hospital, North West Ethiopia: A comparative cross-sectional study. AIDS research and treatment. 2016;2016.

Owiredu DWK, Quaye L, Amidu N. Oxidative stress and Dyslipidaemia among Ghanaian HAART-naïve HIV patients and those on HAART. West African Journal of Pharmacy. 2011;22(1).

Pol S, Lebra P, Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities: Intricacies of the pathogenic mechanisms. Clinical Infectious Diseases. 2004;38(2):S65-S72.

Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New England Journal of Medicine. 2002;346(11):811-20.

Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clinical Infectious Diseases. 2004;38(2): S90-S7.

Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: Diagnosis and management. Current Opinion in Infectious Diseases. 2012;25(1):10-6.

Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Reviews. 2003; 5(1):36-43.

Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrobial agents and chemotherapy. 2002;46(3): 716-23.

Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Jama. 2000;283(1):74-80.

Flexner C. HIV-protease inhibitors. New England Journal of Medicine. 1998; 338(18):1281-93.

IIsu A, Granneman G, Bertz R. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35:275-91.

Cameron W, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. Aids. 1999; 13(2):213-24.

Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P et al. Mechanism of indinavir-induced hyperbilirubinemia. Proceedings of the National Academy of Sciences. 2001;98(22):12671-6.

Rossen RD, Butler WT, Waldman RH, Alford RH, Hornick RB, Togo Y, et al. The proteins in nasal secretion: II. A longitudinal study of IgA and neutralizing antibody levels in nasal washings from men infected with influenza virus. Jama. 1970;211(7):1157-61.

Stiehm ER, Fudenberg HH. Serum levels of immune globulins in health and disease: a survey. Pediatrics. 1966;37(5):715-27.

Ngala RA, Opoku D, Asare G. Effects of HIV infection and highly active antiretroviral therapy (HAART) on the liver of HIV patients. Trends in Medical Research. 2015;10(1):1-11.

Rodriguez-Barradas MC, Alexandraki I, Nazir T, Foltzer M, Musher DM, Brown S, et al. Response of human immuno-deficiency virus–infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clinical Infectious Diseases. 2003;37(3):438-47.

Picker LJ. Immunopathogenesis of acute AIDS virus infection. Current Opinion in Immunology. 2006;18(4):399-405.

Mahato SK, Kumar V, Jagmohankumar, Kumar A. Assessment of liver function Test in AIDS patients taking HAART At Rims Art Centre, Ranchi, Jharkhand, India. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS). 2016;15(12):59-61.

Ayelagbe O, Akerele O, Onuegbu A, Oparinde D. Drug hepatotoxicity in HIV patients on highly active antiretroviral therapy [HAART] in Southwest Nigeria. IOSR-JDMS. 2014;13(5):67-70.

Soriano V, Puoti M, Garcia-Gasco P, Rockstroh JK, Benhamou Y, Barreiro P, et al. Antiretroviral drugs and liver injury. Aids. 2008;22(1):1-13.

Betjes MG, Verhagen DW. Stable improvement of renal function after initiation of highly active anti‐retroviral therapy in patients with HIV‐1‐associated nephropathy. Nephrology Dialysis Transplantation. 2002;17(10):1836-9.

Schwartz EJ, Cara A, Snoeck H, Ross MD, Sunamoto M, Reiser J, et al. Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes. Journal of the American Society of Nephrology. 2001; 12(8):1677-84.

Shahinian V, Rajaraman S, Borucki M, Grady J, Hollander WM, Ahuja TS. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. American Journal of Kidney Diseases. 2000;35(5):884-8.

Kimmel PL. The nephropathies of HIV infection: Pathogenesis and treatment. Current opinion in nephrology and hypertension. 2000;9(2):117-22.